APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for PrEP

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for PrEP Market Outlook and Growth Opportunities 2026

Report ID 173986460429 December 2025199 pages

Choose your research edition.

Industry ResearchDrugs for PrEP Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for PrEP Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for PrEP Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for PrEP Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for PrEP Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Drugs for PrEP market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for PrEP market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for PrEP market include Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, North China Pharmaceutical, Chengdu Brilliant Pharmaceutical, Anhui Baker Biopharmaceutical, Zydus, ViiV Healthcare, Teva and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for PrEP market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for PrEP and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for PrEP sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for PrEP market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for PrEP Segment by Company

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

North China Pharmaceutical

Chengdu Brilliant Pharmaceutical

Anhui Baker Biopharmaceutical

Zydus

ViiV Healthcare

Teva

Mylan

Gilead Sciences

Aurobindo Pharma

Amneal Pharmaceuticals

Drugs for PrEP Segment by Type

Oral Drugs

Injections

Drugs for PrEP Segment by Application

Hospital and Clinic

Pharmacy

Other

Drugs for PrEP Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for PrEP status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for PrEP market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for PrEP significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for PrEP competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for PrEP.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for PrEP market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for PrEP industry.

Chapter 3: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for PrEP in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for PrEP Industry Trends Table 2. Drugs for PrEP Industry Drivers Table 3. Drugs for PrEP Industry Opportunities and Challenges Table 4. Drugs for PrEP Industry Restraints Table 5. Global Drugs for PrEP Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for PrEP Revenue Share by Company (2021-2026) Table 7. Global Drugs for PrEP Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Drugs for PrEP Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for PrEP Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Drugs for PrEP Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for PrEP Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for PrEP Company, Product Type & Application Table 13. Global Drugs for PrEP Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for PrEP by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Drugs Table 18. Significant Companies of Injections Table 19. Global Drugs for PrEP Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Drugs for PrEP Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Drugs for PrEP Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Drugs for PrEP Sales Volume Share by Type (2021-2026) Table 23. Global Drugs for PrEP Sales Volume Share by Type (2027-2032) Table 24. Global Drugs for PrEP Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for PrEP Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Drugs for PrEP Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Drugs for PrEP Sales Value Share by Type (2021-2026) Table 28. Global Drugs for PrEP Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Drugs for PrEP Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Drugs for PrEP Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Drugs for PrEP Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Drugs for PrEP Sales Volume Share by Application (2021-2026) Table 36. Global Drugs for PrEP Sales Volume Share by Application (2027-2032) Table 37. Global Drugs for PrEP Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Drugs for PrEP Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Drugs for PrEP Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Drugs for PrEP Sales Value Share by Application (2021-2026) Table 41. Global Drugs for PrEP Sales Value Share by Application (2027-2032) Table 42. Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Drugs for PrEP Sales by Region (2021-2026) & (K Units) Table 44. Global Drugs for PrEP Sales Market Share by Region (2021-2026) Table 45. Global Drugs for PrEP Sales by Region (2027-2032) & (K Units) Table 46. Global Drugs for PrEP Sales Market Share by Region (2027-2032) Table 47. Global Drugs for PrEP Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Drugs for PrEP Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Drugs for PrEP Sales Value Share by Region (2021-2026) Table 50. Global Drugs for PrEP Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Drugs for PrEP Sales Value Share by Region (2027-2032) Table 52. Global Drugs for PrEP Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Drugs for PrEP Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Drugs for PrEP Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 57. Global Drugs for PrEP Sales Market Share by Country (2021-2026) Table 58. Global Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 59. Global Drugs for PrEP Sales Market Share by Country (2027-2032) Table 60. Global Drugs for PrEP Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Drugs for PrEP Sales Value Market Share by Country (2021-2026) Table 62. Global Drugs for PrEP Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Drugs for PrEP Sales Value Market Share by Country (2027-2032) Table 64. Chia Tai Tianqing Pharmaceutical Company Information Table 65. Chia Tai Tianqing Pharmaceutical Business Overview Table 66. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio Table 68. Chia Tai Tianqing Pharmaceutical Recent Development Table 69. Qilu Pharmaceutical Company Information Table 70. Qilu Pharmaceutical Business Overview Table 71. Qilu Pharmaceutical Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Qilu Pharmaceutical Drugs for PrEP Product Portfolio Table 73. Qilu Pharmaceutical Recent Development Table 74. North China Pharmaceutical Company Information Table 75. North China Pharmaceutical Business Overview Table 76. North China Pharmaceutical Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. North China Pharmaceutical Drugs for PrEP Product Portfolio Table 78. North China Pharmaceutical Recent Development Table 79. Chengdu Brilliant Pharmaceutical Company Information Table 80. Chengdu Brilliant Pharmaceutical Business Overview Table 81. Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio Table 83. Chengdu Brilliant Pharmaceutical Recent Development Table 84. Anhui Baker Biopharmaceutical Company Information Table 85. Anhui Baker Biopharmaceutical Business Overview Table 86. Anhui Baker Biopharmaceutical Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio Table 88. Anhui Baker Biopharmaceutical Recent Development Table 89. Zydus Company Information Table 90. Zydus Business Overview Table 91. Zydus Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Zydus Drugs for PrEP Product Portfolio Table 93. Zydus Recent Development Table 94. ViiV Healthcare Company Information Table 95. ViiV Healthcare Business Overview Table 96. ViiV Healthcare Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ViiV Healthcare Drugs for PrEP Product Portfolio Table 98. ViiV Healthcare Recent Development Table 99. Teva Company Information Table 100. Teva Business Overview Table 101. Teva Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Teva Drugs for PrEP Product Portfolio Table 103. Teva Recent Development Table 104. Mylan Company Information Table 105. Mylan Business Overview Table 106. Mylan Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Mylan Drugs for PrEP Product Portfolio Table 108. Mylan Recent Development Table 109. Gilead Sciences Company Information Table 110. Gilead Sciences Business Overview Table 111. Gilead Sciences Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Gilead Sciences Drugs for PrEP Product Portfolio Table 113. Gilead Sciences Recent Development Table 114. Aurobindo Pharma Company Information Table 115. Aurobindo Pharma Business Overview Table 116. Aurobindo Pharma Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Aurobindo Pharma Drugs for PrEP Product Portfolio Table 118. Aurobindo Pharma Recent Development Table 119. Amneal Pharmaceuticals Company Information Table 120. Amneal Pharmaceuticals Business Overview Table 121. Amneal Pharmaceuticals Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Amneal Pharmaceuticals Drugs for PrEP Product Portfolio Table 123. Amneal Pharmaceuticals Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Drugs for PrEP Distributors List Table 127. Drugs for PrEP Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Drugs for PrEP Product Image Figure 2. Global Drugs for PrEP Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for PrEP Sales (2021-2032) & (K Units) Figure 5. Global Drugs for PrEP Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Drugs for PrEP Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Drugs Image Figure 10. Injections Image Figure 11. Global Drugs for PrEP Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Drugs for PrEP Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for PrEP Sales Volume Share by Type (2021-2032) Figure 14. Global Drugs for PrEP Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Drugs for PrEP Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for PrEP Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Drugs for PrEP Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Drugs for PrEP Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs for PrEP Sales Volume Share by Application (2021-2032) Figure 23. Global Drugs for PrEP Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Drugs for PrEP Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs for PrEP Sales Value Share by Application (2021-2032) Figure 26. Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Drugs for PrEP Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Drugs for PrEP Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Drugs for PrEP Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 31. North America Drugs for PrEP Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Drugs for PrEP Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Drugs for PrEP Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 37. South America Drugs for PrEP Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Drugs for PrEP Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Drugs for PrEP Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Drugs for PrEP Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Drugs for PrEP Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Drugs for PrEP Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Drugs for PrEP Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Drugs for PrEP Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Qilu Pharmaceutical
  • North China Pharmaceutical
  • Chengdu Brilliant Pharmaceutical
  • Anhui Baker Biopharmaceutical
  • Zydus
  • ViiV Healthcare
  • Teva
  • Mylan
  • Gilead Sciences
  • Aurobindo Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for PrEP Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for PrEP Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for PrEP Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for PrEP Market Dynamics
  1. 2.1 Drugs for PrEP Industry Trends
  2. 2.2 Drugs for PrEP Industry Drivers
  3. 2.3 Drugs for PrEP Industry Opportunities and Challenges
  4. 2.4 Drugs for PrEP Industry Restraints
3 Drugs for PrEP Market by Company
  1. 3.1 Global Drugs for PrEP Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for PrEP Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for PrEP Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for PrEP Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for PrEP Company Ranking (2024-2026)
  6. 3.6 Global Drugs for PrEP Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for PrEP Company Product Type and Application
  8. 3.8 Global Drugs for PrEP Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for PrEP Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for PrEP Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for PrEP Market by Type
  1. 4.1 Drugs for PrEP Type Introduction
  2. 4.1.1 Oral Drugs
  3. 4.1.2 Injections
  4. 4.2 Global Drugs for PrEP Sales Volume by Type
  5. 4.2.1 Global Drugs for PrEP Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for PrEP Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Drugs for PrEP Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Drugs for PrEP Sales Value by Type
  9. 4.3.1 Global Drugs for PrEP Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs for PrEP Sales Value by Type (2021-2032)
  11. 4.3.3 Global Drugs for PrEP Sales Value Share by Type (2021-2032)
5 Drugs for PrEP Market by Application
  1. 5.1 Drugs for PrEP Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Drugs for PrEP Sales Volume by Application
  6. 5.2.1 Global Drugs for PrEP Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for PrEP Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Drugs for PrEP Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Drugs for PrEP Sales Value by Application
  10. 5.3.1 Global Drugs for PrEP Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for PrEP Sales Value by Application (2021-2032)
  12. 5.3.3 Global Drugs for PrEP Sales Value Share by Application (2021-2032)
6 Drugs for PrEP Regional Sales and Value Analysis
  1. 6.1 Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for PrEP Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for PrEP Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for PrEP Sales by Region (2027-2032)
  5. 6.3 Global Drugs for PrEP Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for PrEP Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for PrEP Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for PrEP Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for PrEP Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for PrEP Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for PrEP Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for PrEP Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for PrEP Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for PrEP Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for PrEP Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for PrEP Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for PrEP Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for PrEP Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for PrEP Sales Value Share by Country, 2025 VS 2032
7 Drugs for PrEP Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for PrEP Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for PrEP Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for PrEP Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for PrEP Sales by Country (2027-2032)
  6. 7.4 Global Drugs for PrEP Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for PrEP Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for PrEP Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for PrEP Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for PrEP Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for PrEP Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for PrEP Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for PrEP Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for PrEP Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for PrEP Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for PrEP Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for PrEP Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for PrEP Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for PrEP Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for PrEP Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for PrEP Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for PrEP Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for PrEP Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for PrEP Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for PrEP Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for PrEP Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for PrEP Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for PrEP Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for PrEP Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for PrEP Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for PrEP Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for PrEP Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for PrEP Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for PrEP Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for PrEP Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for PrEP Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for PrEP Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for PrEP Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Qilu Pharmaceutical
  8. 8.2.1 Qilu Pharmaceutical Company Information
  9. 8.2.2 Qilu Pharmaceutical Business Overview
  10. 8.2.3 Qilu Pharmaceutical Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical Recent Developments
  13. 8.3 North China Pharmaceutical
  14. 8.3.1 North China Pharmaceutical Company Information
  15. 8.3.2 North China Pharmaceutical Business Overview
  16. 8.3.3 North China Pharmaceutical Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
  18. 8.3.5 North China Pharmaceutical Recent Developments
  19. 8.4 Chengdu Brilliant Pharmaceutical
  20. 8.4.1 Chengdu Brilliant Pharmaceutical Company Information
  21. 8.4.2 Chengdu Brilliant Pharmaceutical Business Overview
  22. 8.4.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
  24. 8.4.5 Chengdu Brilliant Pharmaceutical Recent Developments
  25. 8.5 Anhui Baker Biopharmaceutical
  26. 8.5.1 Anhui Baker Biopharmaceutical Company Information
  27. 8.5.2 Anhui Baker Biopharmaceutical Business Overview
  28. 8.5.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
  30. 8.5.5 Anhui Baker Biopharmaceutical Recent Developments
  31. 8.6 Zydus
  32. 8.6.1 Zydus Company Information
  33. 8.6.2 Zydus Business Overview
  34. 8.6.3 Zydus Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Drugs for PrEP Product Portfolio
  36. 8.6.5 Zydus Recent Developments
  37. 8.7 ViiV Healthcare
  38. 8.7.1 ViiV Healthcare Company Information
  39. 8.7.2 ViiV Healthcare Business Overview
  40. 8.7.3 ViiV Healthcare Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 ViiV Healthcare Drugs for PrEP Product Portfolio
  42. 8.7.5 ViiV Healthcare Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Drugs for PrEP Product Portfolio
  48. 8.8.5 Teva Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Drugs for PrEP Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Gilead Sciences
  56. 8.10.1 Gilead Sciences Company Information
  57. 8.10.2 Gilead Sciences Business Overview
  58. 8.10.3 Gilead Sciences Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Gilead Sciences Drugs for PrEP Product Portfolio
  60. 8.10.5 Gilead Sciences Recent Developments
  61. 8.11 Aurobindo Pharma
  62. 8.11.1 Aurobindo Pharma Company Information
  63. 8.11.2 Aurobindo Pharma Business Overview
  64. 8.11.3 Aurobindo Pharma Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
  66. 8.11.5 Aurobindo Pharma Recent Developments
  67. 8.12 Amneal Pharmaceuticals
  68. 8.12.1 Amneal Pharmaceuticals Company Information
  69. 8.12.2 Amneal Pharmaceuticals Business Overview
  70. 8.12.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
  72. 8.12.5 Amneal Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for PrEP Value Chain Analysis
  2. 9.1.1 Drugs for PrEP Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for PrEP Sales Mode & Process
  6. 9.2 Drugs for PrEP Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for PrEP Distributors
  9. 9.2.3 Drugs for PrEP Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst